Abbott ABT Established Pharmaceuticals — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Abbott's established pharmaceuticals — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Abbott's established pharmaceuticals — net sales?
- Abbott (ABT) reported established pharmaceuticals — net sales of $1.43B in Q1 2026.
- How has Abbott's established pharmaceuticals — net sales changed year-over-year?
- Abbott's established pharmaceuticals — net sales increased by 13.2% year-over-year, from $1.26B to $1.43B.
- What is the long-term trend for Abbott's established pharmaceuticals — net sales?
- Over 4 years (2021 to 2025), Abbott's established pharmaceuticals — net sales has grown at a 4.1% compound annual growth rate (CAGR), from $4.72B to $5.54B.
- What does established pharmaceuticals — net sales mean?
- Total revenue earned from the sale of established pharmaceutical products.
- How do you interpret established pharmaceuticals — net sales?
- An increase suggests strong demand or successful expansion in international markets, while a decrease may indicate competitive pressure or patent expirations.
- How does established pharmaceuticals — net sales compare across companies?
- Comparable to revenue metrics for generic or mature drug divisions at other global pharmaceutical companies.